Trial · NCT02791334
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT02791334, Phase 1, Completed, Eli Lilly and Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors. Trials, record NCT02791334. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02791334
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- NCT number
- NCT02791334
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 164 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
- Interventions
- LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367
- First posted
- 2016-06-06
- Last updated
- 2024-09-27
- Other registries' IDs
- eudract:2016-000440-33
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs) | Baseline through Cycle 1 (Approximately 28 Days) | |
| Secondary | Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3300054 | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) | |
| Secondary | PK: Cmax of Ramucirumab | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) | |
| Secondary | PK: Cmax of Abemaciclib | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) | |
| Secondary | PK: Cmax of Merestinib | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) | |
| Secondary | PK: Cmax of LY3321367 | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) | |
| Secondary | Objective Response Rate (ORR): Proportion of Participants With a Complete Response (CR) or Partial Response (PR) | Baseline to Measured Progressive Disease (Approximately 6 Months ) | |
| Secondary | Progression Free Survival (PFS) | Baseline to Measured Progressive Disease or Death (Approximately 12 Months) | |
| Secondary | Duration of Response (DoR) | Date of CR or PR to Date of Measured Progressive Disease or Death Due to Any Cause (Approximately 12 Months) | |
| Secondary | Time to Response (TTR) | Baseline to Date of CR or PR (Approximately 6 Months) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02791334
GET https://conductscience.org/api/trials/v1/NCT02791334/registered